GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Excelsior Biopharma 6496.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

23.85

+3.47%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Excelsior Biopharma

Its shares trade on Taipei Exchange under the ticker 6496.TWO. It has been listed since 19 December 2014. In the fiscal year to 31 December 2025, it reported revenue of TWD 898.3m and a net loss of TWD 183.2m. At that date it held total assets of TWD 1.48bn and shareholders' equity of TWD 804.2m.

Excelsior Biopharma Inc. engages in the research, development, manufacture, and distribution of pharmaceutical products. The company is headquartered in Taipei City, Taipei. The company went IPO on 2014-12-19. The firm's main products include prescription drugs, non-prescription drugs, health care products, medical equipment and rapid test reagents. The firm distributes its product in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
19 Dec 2014

Leadership

Pay as last reported

  • Zemin ChenChairman of the Board, General Manager, Deputy General Manager-Business Division, since 2020
  • Mingce ChenFinance Manager
  • Zhanghui DaiDeputy General Manager
  • Bizhu CaiDirector
  • Jialin ChenDirector
  • Mr. Xiang-Min HuangDirector
  • Huizhen LiuDirector
  • Donglong XuDirector, since 2024
  • Zhaoqin YangDirector
  • Mr. Chi-Feng HungIndependent Director
  • Tianyi LuoIndependent Director
  • Mr. Ying-Chou WangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Excelsior Biopharma Inc. develops prescription drugs for domestic and overseas markets.
  • The company manufactures non-prescription drugs and health care products in Taipei City.
  • Excelsior Biopharma Inc. distributes medical equipment and rapid test reagents globally.

Weaknesses

  • The company's products are limited to pharmaceuticals without diversification.
  • Excelsior Biopharma Inc. relies on Taipei City for manufacturing operations.
  • The firm has no presence in emerging markets beyond domestic and overseas distribution.

Opportunities

  • Expanding into new markets for prescription drugs in Asia-Pacific regions.
  • Increasing demand for rapid test reagents in global health crises.
  • Growing market for health care products in Taiwan's domestic market.

Threats

  • Competition from established pharmaceutical firms in Health Care sector.
  • Regulatory changes affecting pharmaceutical distribution in Taiwan.
  • Economic downturns impacting global health care spending.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.